SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.) *

Wave Life Sciences Ltd.			
(Name of Issuer)			
\$0 Par Value Ordinary Shares			
(Title of Class of Securities)			
Y95308105			
(CUSIP Number)			
March 30, 2021			
(Date of Event Which Requires Filing of this Statement)			
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:			
□ Rule 13d-1(b)			
⊠ Rule 13d-1(c)			
☐ Rule 13d-1(d)			
(Page 1 of 9 Pages)			

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	NAME OF REPORTING I.R.S. IDENTIFICATION	NG PERSONS ON NO. OF ABOVE PERSONS (ENTITIES ONLY)			
	Deerfield Mgmt, L.P.				
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware				
	5.	SOLE VOTING POWER			
NUMBER OF		0			
SHARES BENEFICIALLY	6.	SHARED VOTING POWER			
OWNED BY		3,910,430 (1)			
EACH REPORTING	7.	SOLE DISPOSITIVE POWER			
PERSON		0			
WITH	8.	SHARED DISPOSITIVE POWER			
		3,910,430 (1)			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	3,910,430 (1)				
10.		AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*			
		• •			
11.	PERCENT OF CLASS	REPRESENTED BY AMOUNT IN ROW 9			
	7.98%				
12.	TYPE OF REPORTING PERSON*				
	PN				

⁽¹⁾ Comprised of ordinary shares held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

1.	NAME OF DEDODTIN	IC DED CONC			
1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)				
	I.R.S. IDENTIFICATION NO. OF ABOVE LERSONS (ENTITIES ONEL)				
	Deerfield Management	Company, L.P.			
2.	CHECK THE APPROP	PRIATE BOX IF A MEMBER OF A GROUP*	(a) □		
			(b) ⊠		
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware	COLE MOTIVO DOLUTE			
	5.	SOLE VOTING POWER			
NUMBER OF		0			
SHARES	6.	SHARED VOTING POWER			
BENEFICIALLY OWNED BY					
EACH	_	3,910,430 (2)			
REPORTING	7.	SOLE DISPOSITIVE POWER			
PERSON WITH		0			
WIIII	8.	SHARED DISPOSITIVE POWER			
		3,910,430 (2)			
9.	AGGREGATE AMOU	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
5.	AGGREGATE AMOUNT BENEFICIALET OWNED BY EACH REPORTING LERSON				
	3,910,430 (2)				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* □				
11.	PERCENT OF CLASS	REPRESENTED BY AMOUNT IN ROW 9			
	7.98% (2)				
12.	TYPE OF REPORTING PERSON*				
	PN				

⁽²⁾ Comprised of ordinary shares held by Deerfield Partners, L.P., of which Deerfield Management Company, L.P. is the investment advisor.

1.	NAME OF REPORTIN	IC DEDSONS			
1.		ON NO. OF ABOVE PERSONS (ENTITIES ONLY)			
	I.K.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES UNLI)				
	Deerfield Partners, L.P.				
2.	CHECK THE APPRO	PRIATE BOX IF A MEMBER OF A GROUP*	(a) 🗆		
			(b) ⊠		
	CEC LICE ONLY				
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PL	ACE OF ORGANIZATION			
	Delaware				
	5.	SOLE VOTING POWER			
NUMBER OF		0			
SHARES	6.	SHARED VOTING POWER			
BENEFICIALLY OWNED BY					
EACH		3,910,430			
REPORTING	7.	SOLE DISPOSITIVE POWER			
PERSON WITH		0			
WIIII	8.	SHARED DISPOSITIVE POWER			
		2 242 422			
	A CODECATE A MOL	3,910,430			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	3,910,430				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	7.98%				
12.	TYPE OF REPORTIN	G PERSON*			
	PN				

H					
1.	NAME OF REPORTIN				
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)				
	James E. Flynn				
2.	CHECK THE APPROI	PRIATE BOX IF A MEMBER OF A GROUP*	(a) 🗆		
			(b) ⊠		
3.	SEC USE ONLY				
J.	SEC USE OIVET				
4.	CITIZENSHIP OR PL.	ACE OF ORGANIZATION			
	United States				
	5.	SOLE VOTING POWER			
NUMBER OF		0			
SHARES	6.	SHARED VOTING POWER			
BENEFICIALLY OWNED BY					
EACH		3,910,430 (3)			
REPORTING	7.	SOLE DISPOSITIVE POWER			
PERSON WITH		0			
	8.	SHARED DISPOSITIVE POWER			
		3,910,430 (3)			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	2 010 420 (2)				
10.	3,910,430 (3)				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* □				
11.	PERCENT OF CLASS	REPRESENTED BY AMOUNT IN ROW 9			
	7.98% (3)				
12.	TYPE OF REPORTING	G PERSON*			
	IN				
1	1 = :				

⁽³⁾ Comprised of ordinary shares held by Deerfield Partners, L.P.

CUSIP No.	Y95308105	13G	Page 6 of 9
Item 1(a).	Name of Issuer:		
	Wave Life Sciences Ltd.		
Item 1(b).	Address of Issuer's Princip	pal Executive Offices:	
	7 Straits View #12-00, Ma	ırina One	
	East Tower Singapore 018936		
Item 2(a).	Name of Person Filing:		
	James E. Flynn, Deerfield	Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L	L.P.
Item 2(b).	Address of Principal Busin	ness Office, or if None, Residence:	
	James E. Flynn, Deerfield York, NY 10010	Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, 3	345 Park Avenue South, 12th Floor, New
Item 2(c).	Citizenship:		
	Deerfield Mgmt, L.P., Dee	erfield Management Company, L.P. and Deerfield Partners, L.P Delaware li	imited partnerships;
	James E. Flynn – United S	States citizen	
Item 2(d).	Title of Class of Securities	s:	
	\$0 Par Value Ordinary Sha	ares	
Item 2(e).	CUSIP Number:		
	Y95308105		
Item 3.	If This Statement is Filed	Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Fili	ing is a:
(a)	☐ Broker or dealer reg	gistered under Section 15 of the Exchange Act.	
(b)	\square Bank as defined in S	Section 3(a)(6) of the Exchange Act.	
(c)	☐ Insurance company	as defined in Section 3(a)(19) of the Exchange Act.	
(d)	☐ Investment compan	y registered under Section 8 of the Investment Company Act.	
(e)	☐ An investment advis	ser in accordance with Rule 13d-1(b)(1)(ii)(E);	
(f)	☐ An employee benefi	it plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);	
(g)	☐ A parent holding co	mpany or control person in accordance with Rule 13d-1(b)(1)(ii)(G);	

Deerfield Partners, L.P. - 3,910,430 James E. Flynn – 3,910,430

13G

CUSIP No.

Y95308105

^{**}See footnotes on cover pages which are incorporated by reference herein.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following \Box .

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit B

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Date: April 9, 2021

Exhibit List

Exhibit A. Joint Filing Agreement.

Exhibit B. Item 8 Statement.

Exhibit C. Power of Attorney (1).

(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.

Joint Filing Agreement

The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Ordinary Shares of Wave Life Sciences Ltd. shall be filed on behalf of the undersigned.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Exhibit B

Due to the relationship	s between them, the reporting	persons hereunder may	be deemed to constitute a	"group" wi	th one another fo	or purposes of
Section 13(d)(3) of the Securities	es Exchange Act of 1934.					